Table 2.
Baseline and 3-month data of patients during Glicoset® 1000 treatment and placebo.
| Parameters | Glicoset® 1000 | Placebo | ||
|---|---|---|---|---|
| Baseline | 3 Months | Baseline | 3 Months | |
| Patients | 72 | 71 | 76 | 72 |
| M/F | 35/37 | 35/36 | 38/38 | 35/37 |
| Smoking status (M/F) | 14/16 | 14/16 | 13/12 | 12/11 |
| IFG (M/F (%)) | 20/18 (52.8) | 13/11 (33.8) | 21/18 (51.3) | 16/14 (41.7) |
| IGT (M/F (%)) | 15/19 (47.2) | 13/16 (40.8) | 17/20 (48.7) | 19/19 (52.8) |
| EU from IFG (M/F (%)) | - | 7/6 (18.3) | - | 0/0 |
| EU from IGT (M/F (%)) | - | 2/3 (7.0) | - | 0/0 |
| IGT from IFG (M/F (%)) | - | 0/0 | - | 3/3 (8.3) |
| D from IFG (M/F (%)) | - | 0/0 | - | 0/0 |
| D from IGT (M/F (%)) | - | 0/0 | - | 1/3 (5.6) |
| Lost to FU from IFG (M/F (%)) | - | 0/1 (1.4) | - | 2/1 (4.2) |
| Lost to FU from IGT (M/F (%)) | - | 0/0 | - | 0/1 (1.4) |
M: males; F: females; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; EU: euglycemia; D: diabetes; FU: follow-up.